I'm not sure some of your statements are more than

I'm not sure some of your statements are more than just rumors. We do not know Incell DX's pricing was an issue. What Nader said in the last CC was that the FDA did not accept BP's occupancy test because it was not used through out the trial for all patients. He said the FDA did not approve of this, not the test is not approved. The FDA, at least my understanding, wants a consistent level of data, tools used, criteria, etc.. from beginning to end and changing anything can dis-connect the resulting data. If it was Incell DX's occupancy test that held up the BLA, I can see why Nader is not super crazy about paying his bill, IF that is actually the case. Lets keep in mind that the financial status between Cytodyn and Incell DX is not know and is all rumor also.

Bruce has a solid reason to defend his occupancy test, and Cytodyn has a good reason to move away from Incell to get the BLA done. Incell DX is a vendor, that is all. What Bruce wants access to is his own business. Cytodyn is doing what it needs to to get a delayed BLA done and a Covid approval. Cytodyn is not in business to help Bruce.